✦ LIBER ✦

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

✍ Scribed by Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 92 KB
Volume: 40
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.20420

No coin nor oath required. For personal study only.

✦ Synopsis

The therapeutic efficacy of angiotensin II receptor antagonist, losartan, was studied in patients with nonalcoholic steatohepatitis (NASH). Seven patients with both NASH and hypertension were treated with losartan (50 mg/d) for 48 weeks. Treatment with losartan resulted in a significant decrease in blood markers of hepatic fibrosis, plasma TGF-␤1 and serum ferritin concentration concurrently with an improvement in serum aminotransferase levels. Histological assessment showed improvement of hepatic necroinflammation in five patients, reduction of hepatic fibrosis in four patients, and disappearance of iron deposition in two patients. No side effect of treatment was noted at any time during the study. In conclusion, the present data raise the possibility that an angiotensin II receptor antagonist may be therapeutically efficacious for NASH. (HEPATOLOGY 2004;40:1222-1225.

📜 SIMILAR VOLUMES

Targeting the renin-angiotensin system:

Targeting the renin-angiotensin system: Potential beneficial effects of the angiotensin II receptor blockers in patients with nonalcoholic steatohepatitis

✍ Silvia Sookoian; Carlos J. Pirola 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 1 views

We read with great interest the recent report by Li et al. 1 analyzing the correlation between the clusters of differentiation 24 (CD24) polymorphism and risk of chronic hepatitis B virus (HBV) infection. In their study, the CD24 P170 T allele (thymidine at position 170) was correlated with a strong

Effect of losartan, an Angiotensin II re

Effect of losartan, an Angiotensin II receptor antagonist, on portal pressure in cirrhosis

✍ Arved Winfried Schneider; Johann Friedrich Kalk; Christian Peter Klein 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

Administration of angiotensin II causes an increase in portal pressure, and plasma concentration of angiotensin II is elevated in patients with cirrhosis, suggesting that angiotensin II may be involved in the pathogenesis of portal hypertension in cirrhosis. We evaluated the effect of the orally act

The pharmacokinetics and metabolism of C

The pharmacokinetics and metabolism of CP-191,166, an angiotensin II receptor antagonist, in rats and dogs

✍ Mary C. Allen; Mark R. Nocerini; Wesley W. Day 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

166 is an orally active, non-peptide angiotensin II (AII) receptor antagonist developed for the treatment of hypertension and congestive heart failure (CHF). In this study, the intravenous (iv) and oral (po) single dose pharmacokinetics (PK), oral multiple dose PK and P450-mediated metabolism of 16

Effects of angiotensin II receptor antag

Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria

✍ Kathryn C. B. Tan; Wing-Sun Chow; Victor H. G. Ai; Karen S. L. Lam 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

ChemInform Abstract: Discovery of GSK345

ChemInform Abstract: Discovery of GSK345931A: An EP1 Receptor Antagonist with Efficacy in Preclinical Models of Inflammatory Pain.

✍ Adrian Hall; et al. et al. 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 18 KB 👁 1 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v

Effect of Telenzepine, an M1-Selective M

Effect of Telenzepine, an M1-Selective Muscarinic Receptor Antagonist, in Patients with Nocturnal Asthma

✍ M. Cazzola; M.G. Matera; G. Liccardi; G. Sacerdoti; G. D'Amato; F. Rossi 📂 Article 📅 1994 🏛 Elsevier 🌐 English ⚖ 346 KB

Muscarinic M1-receptor antagonists can prevent the induction of a long-lasting excitatory postsynaptic potential in autonomic ganglia. As the prolonged occupation of M1-receptors is a possible protective mechanism against vagal overstimulation, M1-antagonists might prove to be effective in preventin